
Nautilus Biotechnology, Inc.: updates and filings
Price
$2.12
November 20, 2026Market cap $268M
What Ploutos Investor adds for Nautilus Biotechnology
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 27% since Oct 27, 2026, when the 10-Q these figures come from was filed ($2.89 then, $2.12 on Nov 20, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 27, 2026next Jan 27, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
October 2026
July 2026
April 2026
February 2026
November 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 3, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Oct 27, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 27, 2026Results of operationsForm8-K
- Sep 18, 2026FilingFormEFFECT
- Sep 11, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Sep 11, 2026Material agreement entered, material agreement endedForm8-K
- Sep 11, 2026Shelf registration for future offeringsFormS-3
- Aug 28, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 14, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jul 28, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 28, 2026Results of operationsForm8-K
- Jun 30, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jun 18, 2026Shareholder voteForm8-K
- Jun 4, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Apr 28, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 28, 2026Results of operationsForm8-K
- Mar 4, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Mar 4, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Feb 26, 2026Shares registered for employeesFormS-8
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 26, 2026Results of operationsForm8-K
- Nov 4, 2025Other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 3, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Oct 27, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 27, 2026 | 8-K | Results of operations | Document |
| Sep 18, 2026 | EFFECT | Filing | Document |
| Sep 11, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Sep 11, 2026 | 8-K | Material agreement entered, material agreement ended | Document |
| Sep 11, 2026 | S-3 | Shelf registration for future offerings | Document |
| Aug 28, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jul 28, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 28, 2026 | 8-K | Results of operations | Document |
| Jun 30, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jun 18, 2026 | 8-K | Shareholder vote | Document |
| Jun 4, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Apr 28, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 28, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 28, 2026 | 8-K | Results of operations | Document |
| Mar 4, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Mar 4, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Feb 26, 2026 | S-8 | Shares registered for employees | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 26, 2026 | 8-K | Results of operations | Document |
| Nov 4, 2025 | 8-K | Other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 17, 2020.
The full analysis
What do Nautilus Biotechnology's filings show?
The filings are where every one of Nautilus Biotechnology's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.